The potential efficacy of oral l-deprenyl (5 mg b.i.d.) added to the
regimen of 10 patients with Alzheimer's disease receiving either tacrine or
physostigmine was assessed in a double-blind, placebo- controlled, 4-week,
two-period crossover pilot study. l-Deprenyl was associated with
significant improvement in scores on the cognitive subscale of the
Alzheimer's Disease Assessment Scale, suggesting possible additive effects
of l-deprenyl to the effects of cholinesterase inhibitors.